GCG and Parkinson disease: Furthermore, a randomized clinical trial of the glucagon-like peptide-1 agonist exenatide in Parkinson's disease (PD) patients revealed changes in the expression and phosphorylation levels of several proteins in NDEVs during 48 weeks of treatment (Athauda et al., 2019).